A call to neuroscientists to help reveal root causes of chemobrain

A substantial fraction of non-central nervous system cancer survivors, especially those who have received chemotherapy, experience long-lasting cognitive difficulties, including problems with concentration, word-finding, short-term memory, and multitasking. Though well documented, cancer-related cognitive impairment (CRCI), known colloquially as chemobrain or chemofog, remains a mystery regarding its underlying neurological causes. In a Forum paper published June 12 in the journal Trends […]

Continue reading »

CDC: invasive MRSA more likely among injection drug users

(HealthDay)—Injection drug users are more than 16-fold more likely to develop invasive methicillin-resistant Staphylococcus aureus (MRSA) infections, according to research published in the June 8 issue of the U.S. Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report. Kelly A. Jackson, M.P.H., from the CDC in Atlanta, and colleagues examined the effect of the opioid epidemic on invasive […]

Continue reading »

The Best Baby Carriers on the Market in 2018

What did we ever do before baby carriers? JK. They’ve been around since the dawn of time — and they’ve only gotten fancier. Babywearing is often a parent’s go-to when little ones are fussy (or sleepy or on the move or want to face forward or… anything, really). Also, babywearing makes traveling and shopping way easier because you don’t have to […]

Continue reading »

Genetic discovery will help clinicians identify aggressive versus benign bone tumors

The first genetic marker for the bone tumour, osteoblastoma, has been discovered by scientists at the Wellcome Sanger Institute and their collaborators. Whole-genome and transcriptome sequencing of human bone tumours revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results, published in Nature Communications, will help clinicians correctly distinguish benign osteoblastoma […]

Continue reading »

Newly-approved therapy provides improved quality of life for midgut neuroendocrine tumor patients

Midgut neuroendocrine tumors are a rare type of cancer that develops in the small intestine and colon. Roughly 12,000 people are diagnosed with this disease each year. In January, the United Stated Food and Drug Administration approved Lutathera, a first-of-its-kind peptide receptor radionuclide therapy. The injection consists of a somatostatin analog combined with a radioactive isotope that directly targets neuroendocrine […]

Continue reading »

Cancer: More targeted use of immunotherapy

Doctors are increasingly fighting cancer by stimulating patients’ immune systems. SNSF-supported researchers have now discovered a method for predicting the likelihood of treatment success. Immunotherapy changes a patient’s immune system to allow it to attack cancer cells and either destroy them or at least keep them from growing. But the therapy only works for a minority of patients. Researchers supported […]

Continue reading »
1 324 325 326 327 328 388